Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study
Open Access
- 5 August 2015
- journal article
- research article
- Published by Elsevier BV in Journal of Autoimmunity
- Vol. 63, 88-93
- https://doi.org/10.1016/j.jaut.2015.07.012
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus–associated cryoglobulinemic vasculitisArthritis & Rheumatism, 2011
- Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patientsAutoimmunity Reviews, 2011
- Relapse of hepatitis C virus–associated mixed cryoglobulinemia vasculitis in patients with sustained viral responseArthritis & Rheumatism, 2008
- Development of type II mixed cryoglobulinaemic syndrome after effective and persistent hepatitis C virus eradicationRheumatology, 2006
- HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferationsLeukemia, 2006
- Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroidsRheumatology, 2006
- Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot studyJournal of Hepatology, 2005
- PEGylated interferon alfa‐2b and ribavirin treatment in patients with hepatitis C virus–related systemic vasculitisArthritis & Rheumatism, 2005
- Efficacy and safety of rituximab in type II mixed cryoglobulinemiaBlood, 2003
- Hepatitis c virus infection in type ii mixed cryoglobulinemiaArthritis & Rheumatism, 1993